Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
GRAIL and Illumina have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. In addition, GRAIL stockholders will receive future payments representing a tiered single-digit percentage of certain GRAIL-related revenues. The agreement has been approved by the Boards of Directors of both companies. “Over the last four years, GRAIL’s talented team has made exceptional progress in developing the technology and clinical data required to launch the Galleri™ multi-cancer screening test. Galleri...